Drug Trial Radar · NCT06369298
Study of JK07 in Patients With Chronic Heart Failure
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Mar 28, 2024
Primary completion
Oct 31, 2026
Study completion Oct 31, 2026
Sponsor
- Lead sponsor
- Salubris Biotherapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.
Conditions
- Heart Failure With Reduced Ejection Fraction
- Heart Failure With Preserved Ejection Fraction
Interventions
JK07Drug
JK07 is a fully human anti-human epidermal growth factor receptor 3 (also known as ErbB3 or HER3) antibody fused with the epidermal growth factor (EGF)-domain of Neuregulin (NRG)-1b protein.
PlaceboDrug
0.9% sodium chloride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Cohort 1Time frame: Study entry through week 52
- Efficacy - Cohort 1Time frame: Baseline through week 26
- Safety - Cohort 2Time frame: Study entry through week 52
Locations
62 sites in 4 countries. Site status is shown where the registry gives one.
Site 121
Alexander City, Alabama
Site 130
Birmingham, Alabama
Site 139
Birmingham, Alabama
Site 138
Huntsville, Alabama
Site 111
Phoenix, Arizona
Site 127
Little Rock, Arkansas
Site 128
Huntington Beach, California
Site 157
Los Angeles, California
Site 158
Orange, California
Site 116
Pasadena, California
Site 129
Santa Maria, California
Site 102
Stanford, California
Site 113
Torrance, California
Site 133
Vista, California
Site 161
Coral Gables, Florida
Site 114
Hialeah, Florida
Site 162
Miami Lakes, Florida
Site 159
Naples, Florida
Site 136
Atlanta, Georgia
Site 143
Boise, Idaho
Site 160
Chicago, Illinois
Site 154
Park Ridge, Illinois
Site 137
Fort Wayne, Indiana
Site 112
Indianapolis, Indiana
Site 104
Covington, Louisiana
Site 118
Baltimore, Maryland
Site 119
Boston, Massachusetts
Site 122
Bloomfield Hills, Michigan
Site 150
Farmington Hills, Michigan
Site 107
Rochester, Minnesota
Site 106
St Louis, Missouri
Site 105
St Louis, Missouri
Site 144
Brick, New Jersey
Site 153
Valhalla, New York
Site 152
Asheville, North Carolina
Site 109
Cary, North Carolina
Site 140
Charlotte, North Carolina
Site 145
Durham, North Carolina
Site 117
Cincinnati, Ohio
Site 100
Cleveland, Ohio
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.